rs6721961 — NFE2L2

Promoter variant reducing NRF2 transcriptional activity by >50%, impairing the master antioxidant response that controls glutathione synthesis, phase II detoxification, and cytoprotective gene expression

See your personal result for NFE2L2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NFE2L2 Promoter — When the Master Antioxidant Switch Is Turned Down

Every cell in your body faces a constant barrage of oxidative stress from metabolism, environmental toxins, and inflammation. The primary defense is NRF211 NRF2
Nuclear factor erythroid 2-related factor 2, encoded by the NFE2L2 gene — the master transcription factor controlling over 200 cytoprotective genes including those responsible for glutathione synthesis, phase II detoxification, heme oxygenase-1, and anti-inflammatory pathways, the master transcription factor that acts like an emergency broadcast system for the body's antioxidant defenses. When a cell detects oxidative stress, NRF2 breaks free from its inhibitor KEAP1, enters the nucleus, and switches on a broad battery of protective genes by binding to antioxidant response elements (AREs)22 antioxidant response elements (AREs)
Short DNA sequences (~23 bases) found in the promoters of NRF2-regulated genes. When NRF2 binds to an ARE, it recruits the transcription machinery to activate gene expression in their promoters.

The rs6721961 variant sits directly within an ARE-like motif in the NFE2L2 promoter itself — a location that appears to serve an auto-regulatory role, allowing NRF2 to amplify its own expression in a positive feedback loop. The T allele disrupts this motif, weakening NRF2's ability to drive its own transcription and blunting the entire downstream cascade.

The Mechanism

The rs6721961 SNP is located at approximately position −617 relative to the NFE2L2 transcription start site (also described as −178 in some coordinate systems based on different reference transcripts). It resides within an ARE-like sequence in the NFE2L2 promoter, a region where NRF2 protein can bind to amplify its own transcription through positive feedback.

In luciferase reporter assays33 luciferase reporter assays
A standard technique where the promoter region of interest is placed upstream of a firefly luciferase gene. The amount of light produced reflects how strongly the promoter drives transcription using human cell lines, Marzec et al. 2007 showed44 Marzec et al. 2007 showed
Marzec JM et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J, 2007 that rs6721961 reduces NFE2L2 promoter activity by over 50% compared to the wild-type G allele. The minor A allele (T on the genomic plus strand) disrupts binding at this site, reducing the auto-regulatory amplification of NRF2 expression. Homozygous AA carriers show substantially lower NRF2 mRNA levels compared to CC or CA genotypes in tissue studies.

The functional consequence extends to the entire NRF2-regulated network: lower NRF2 means less induction of NQO1 (quinone reductase), glutamate-cysteine ligase (rate-limiting enzyme for glutathione synthesis), heme oxygenase-1 (HO-1, anti-inflammatory), and the thioredoxin/sulfiredoxin system. Under normal conditions this reduction may be tolerable; under oxidative challenge — infection, toxin exposure, air pollution, smoking — the buffering capacity is meaningfully lower.

The Evidence

Oxidative stress and diabetes: A study of newly diagnosed type 2 diabetes patients in China by Wang X et al. 201555 Wang X et al. 2015
Wang X et al. Association between the NF-E2 Related Factor 2 Gene Polymorphism and Oxidative Stress, Anti-Oxidative Status, and Newly-Diagnosed Type 2 Diabetes Mellitus in a Chinese Population. Int J Mol Sci, 2015 found that individuals with the AA (TT on plus strand) genotype had significantly lower total antioxidant capacity, superoxide dismutase, catalase, and glutathione peroxidase activity, as well as higher malondialdehyde (a marker of lipid peroxidation) and insulin resistance. This genotype was associated with 1.56-fold increased risk of T2DM (OR 1.56, 95% CI 1.11–2.20).

Neurodegeneration: In Parkinson's disease, the T allele showed a counterintuitive protective association66 counterintuitive protective association
Paul KC et al. NFE2L2, PPARGC1α, and pesticides and Parkinson's disease risk and progression. Mech Ageing Dev, 2018 — carriers had OR 0.70 (95% CI 0.53–0.94) for PD risk and significantly slower cognitive decline (MMSE β=0.095, p=0.0004). This paradox likely reflects the complexity of NRF2 in the brain (some studies show high NRF2 in degenerating neurons) and the specific cellular context of dopaminergic vulnerability.

Cardiovascular: In a Finnish cohort (n=816), the rare TT genotype was associated with an 8.8-fold increased risk of cerebrovascular disease77 8.8-fold increased risk of cerebrovascular disease
Kunnas et al. 2016: TAMRISK study of 816 Finnish subjects showing NRF2 rs6721961 TT genotype associated with cerebrovascular disease compared to GG.

Hormone metabolism and VTE: NFE2L2 carriers using oral estrogens had dramatically increased risk of venous thromboembolism88 dramatically increased risk of venous thromboembolism
Bouligand J et al. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther, 2011 (OR 17.9 versus OR 2.5 in wild-type), likely due to impaired NRF2-dependent hepatic conjugation of estrogen metabolites.

Cancer: The variant allele has been associated with altered NRF2 protein expression in renal cell carcinoma and with hepatocellular carcinoma risk.

Practical Implications

The T allele means your baseline NRF2 expression is reduced, lowering the ceiling for your antioxidant response. This matters most when oxidative load is high: during infections, heavy exercise, air pollution exposure, alcohol consumption, and smoking. The primary intervention strategy is to bypass the reduced NRF2 auto-induction by using dietary and supplemental NRF2 activators that work through the KEAP1 pathway rather than the promoter — these activate NRF2 protein that is already present, circumventing the transcriptional reduction.

Sulforaphane (from broccoli sprouts) is the most potent dietary NRF2 activator, with a concentration required for activation (CD value) of 0.2 μM — roughly 14-fold more potent than curcumin (2.7 μM) and hundreds-fold more potent than EGCG from green tea (>50 μM). Clinical trials have used broccoli sprout extracts delivering approximately 50–200 μmol sulforaphane per dose. For those who cannot or prefer not to rely on food sources, standardized broccoli sprout extract supplements retaining both glucoraphanin and active myrosinase enzyme provide the most reliable delivery.

Interactions

rs6721961 is part of a three-SNP haplotype in the NFE2L2 promoter along with rs35652124 (−214A>G) and rs6706649 (−212G>A). The low-activity haplotype carrying risk alleles at all three positions (referred to as the "GTC" or "AGA" haplotype depending on the coding-strand notation) shows the most severely reduced promoter activity and has been linked to increased disease risk in multiple cohorts. When genotype results are available for all three SNPs, the combined haplotype is more informative than any single variant alone.

NQO1 (rs1800566) is a direct downstream target of NRF2 — reduced NFE2L2 expression leads to less NQO1 induction. In individuals who carry both the NFE2L2 promoter variant and the NQO1 Pro187Ser variant, the combined reduction in NRF2-dependent antioxidant capacity may be substantially greater than either alone.

SOD2 (rs4880) and GPX1 (rs1050450) are also under partial NRF2 regulation. Combined impairment of NRF2 (upstream regulator) with functional variants in these downstream antioxidant enzymes would compound oxidative stress vulnerability across multiple defense layers.

Nutrient Interactions

sulforaphane increased_need
glutathione impaired_conversion

Genotype Interpretations

What each possible genotype means for this variant.

GG Full NRF2 Expression Normal

Normal NFE2L2 promoter activity and full NRF2 antioxidant response

You have two copies of the common G allele, which preserves the ARE-like binding site in the NFE2L2 promoter. Your NRF2 gene can auto-amplify its own expression under stress conditions, supporting a full antioxidant response across more than 200 cytoprotective target genes. About 79% of people globally share this genotype, though frequencies vary by ancestry — approximately 83% of Europeans versus about 53% of East Asians carry two normal copies.

GT Reduced NRF2 Expression Intermediate

Moderately reduced NFE2L2 promoter activity; one impaired NRF2 auto-regulatory copy

The GT heterozygous state produces a mixed result: one allele carries a functional ARE-like promoter sequence capable of NRF2 auto-amplification, while the other does not. The net promoter activity falls between the homozygous states.

Studies of the low-activity haplotype containing rs6721961 show intermediate effects in carriers of one risk allele compared to two, consistent with codominant inheritance. Under normal, low-stress conditions, the reduction in NRF2 capacity may be well compensated by other regulatory pathways. However, the response ceiling under acute oxidative challenge is reduced.

A practical implication is that external NRF2 activators — sulforaphane from broccoli sprouts, curcumin, EGCG — are likely to be beneficial for GT carriers, as these compounds activate NRF2 protein through the KEAP1 pathway rather than through promoter-level auto-induction.

TT Low NRF2 Expression High Risk

Substantially reduced NFE2L2 promoter activity; NRF2 antioxidant response impaired by >50%

The TT homozygous state disrupts the ARE-like motif at both copies of the NFE2L2 promoter, preventing NRF2 from reinforcing its own expression through positive feedback. This bottleneck reduces basal NRF2 levels and severely limits the capacity for transcriptional upregulation under oxidative stress.

The functional consequences documented in clinical studies include: significantly lower total antioxidant capacity, reduced activity of superoxide dismutase, catalase, glutathione, and glutathione peroxidase (Wang X et al. 2015); elevated lipid peroxidation biomarker malondialdehyde; and 1.56-fold increased T2DM risk. In female hemodialysis patients, TT carries significantly elevated blood pressure. The Finnish cerebrovascular study found an 8.8-fold increased risk of cerebrovascular disease for TT versus GG (n=816, p=0.009).

The key therapeutic strategy is to activate NRF2 protein through the KEAP1 pathway rather than waiting for transcriptional auto-induction. Sulforaphane is the most potent food-derived activator: it modifies cysteine residues on KEAP1, causing it to release NRF2, allowing existing NRF2 protein to translocate to the nucleus even when basal transcription is reduced.

Given the dramatically reduced antioxidant capacity, monitoring for markers of oxidative stress is especially warranted if you also carry variants in downstream antioxidant enzymes such as NQO1, SOD2, or GPX1.